EUVIMEDEUVIMED entdecken
Open Access

GLP ‐ 1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models

Caitlin Baumer-Harrison iD, Danya Aldaghma, Alex D White, Sarah V Applebey, Allison M Pataro, Allaha Z Mohiby, Brandon Alonso, Allison G Xiao, Libbey S O'Farrell, Yuewei Qian, Tamer Coskun iD, Matthew P Coghlan und 7 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Caitlin Baumer-Harrison und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Vomiting, Cyclic AMP, Glycemic Control. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Diabetes Research Center, Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists improve glycemic control and promote weight loss in diabetes and obesity but are also associated with gastrointestinal adverse events, including nausea and emesis in many patients. These concerns highlight the need for the development of novel GLP‐1R agonists that minimize these side effects while maintaining beneficial metabolic outcomes. Here, we investigate the in vivo effects of exendin‐4‐Phe1 (Ex‐Phe1), a GLP‐1R biased agonist. Materials and Methods In three pre‐clinical species, mice ( n = 43), rats ( n = 54), and musk shrews ( n = 30), we examined in vivo glycemic control, feeding, and nausea/emesis following native Ex‐4 and Ex‐Phe1 administration. We also used cFos expression following Ex‐4 and Ex‐Phe1 administration to examine neural activation in regions involved in mediating nausea and emetic side effects of GLP‐1R agonism.

Results

In vitro studies show Ex‐Phe1 favors cAMP signaling with reduced β‐arrestin recruitment. Compared to Ex‐4, Ex‐Phe1 produced fewer emetic episodes in musk shrews ( Suncus murinus ) and little to no pica, a proxy for nausea, in rats. Ex‐Phe1 effects on food intake and body weight varied by species, while Ex‐4 and Ex‐Phe1 similarly enhanced glucose tolerance in all species. Ex‐4 and Ex‐Phe1 increased cFos expression within brain regions linked to nausea and emesis in all species.

Conclusions

Collectively, Ex‐Phe1 maintains glycemic benefits in all three species, but putatively blunts the ability of the CNS GLP‐1R+ cells to drive anorexia and weight loss, as well as unwanted adverse events (nausea/emesis) in rats and musk shrews.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsVomitingCyclic AMPGlycemic ControlNauseaHypoglycemic AgentsPeptidesAnimalsRatsShrewsExenatideMaleMiceGlucagon-Like Peptide-1 ReceptorBlood GlucoseVenomsEatingRats, Sprague-Dawley

Stichwörter der Autor:innen

GLP‐1Rbiased agonistemesisexendin‐4malaisenauseaβ‐arrestin

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsExenatideCyclic AMPGlucagon-Like Peptide-1 ReceptorHypoglycemic AgentsBlood GlucosePeptidesVenomsGlp1r protein, rat

Autor:innen und Institutionen

  • Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Division of Diabetes and Complications, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA.
  • Department of Biological Sciences, University of Southern California, Los Angeles, California, USA.
  • Department of Chemistry, Syracuse University, Syracuse, New York, USA.
  • Department of Medicine and Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York, USA.

ORCID-Profile: Caitlin Baumer-Harrison, Tamer Coskun, Bart C De Jonghe, Matthew R Hayes

Förderung

  • NIDDK NIH HHS
  • Diabetes Research Center, Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania

Zitieren

APA

Baumer-Harrison, C., Aldaghma, D., White, A. D., Applebey, S. V., Pataro, A. M., Mohiby, A. Z., Alonso, B., Xiao, A. G., O'Farrell, L. S., Qian, Y., Coskun, T., Coghlan, M. P., Willard, F. S., Ai, M., Sloop, K. W., Doyle, R. P., Borner, T., De Jonghe, B. C., & Hayes, M. R. (2026). GLP ‐ 1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70427

Vancouver

Baumer-Harrison C, Aldaghma D, White AD, Applebey SV, Pataro AM, Mohiby AZ, et al. GLP ‐ 1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70427

BibTeX
@article{BaumerHarrison2026,
  author = {Baumer-Harrison, Caitlin and Aldaghma, Danya and White, Alex D and Applebey, Sarah V and Pataro, Allison M and Mohiby, Allaha Z and Alonso, Brandon and Xiao, Allison G and O'Farrell, Libbey S and Qian, Yuewei and Coskun, Tamer and Coghlan, Matthew P and Willard, Francis S and Ai, Minrong and Sloop, Kyle W and Doyle, Robert P and Borner, Tito and De Jonghe, Bart C and Hayes, Matthew R},
  title = {GLP ‐ 1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70427}
}
Kostenlos starten →